Group 1 - The core viewpoint of the news is that Han's Biotech (03378) has successfully completed its IPO subscription, raising significant interest with a subscription amount of HKD 147.29 billion, leading to an oversubscription of 2,511 times [1] - Han's Biotech plans to issue 18.32 million H-shares, with 10% allocated for public offering, and the share price is set between HKD 28 to HKD 32, aiming to raise up to HKD 590 million [1] - The company has attracted seven cornerstone investors, raising a total of HKD 93.37 million, which accounts for 15.93% of the global offering [1] Group 2 - Since 2016, Han's Biotech has developed a product pipeline that includes one core product and nine other candidate products, focusing on oncology and autoimmune markets [2] - The core product, HX009, is a bispecific antibody fusion protein targeting CD47 and PD-1, which is reported to be leading in clinical trial progress among similar products globally [2] - Financially, Han's Biotech has recorded operating losses with no profits during the reporting period, with losses of RMB 85.16 million, RMB 117 million, and RMB 87.44 million for the fiscal years ending August 31, 2023, 2024, and 2025 respectively [2] Group 3 - The company plans to allocate approximately 35% of the net proceeds from the global offering for the research and development of its core product HX009, 33% for major products HX301 and HX044, 17% for other important products, 5% for commercialization and business development, and 10% for working capital and general corporate purposes [3]
新股消息 | 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍